The clinical experience with antiangiogenic agents.

Antiangiogenic agents have been recently recognized to be potentially useful in the treatment of malignant processes. There has been a resulting flood of these agents into the clinical research field, forcing researchers to consider the unique problems which these agents pose. As these are agents with a novel, angiostatic mechanism of action, new clinical trial designs may become necessary to move these agents from the phase 1 level on to clinical use. Currently, several of these agents are being or have been tested in clinical trials. In this article, we review the available clinical data with antiangiogenic agents from other investigators, and our own experience with pentosan polysulfate.